Unidad de Gestión Clínica Intercentros de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Hospitales Universitarios Virgen Macarena y Virgen del Rocío, Sevilla, Spain.
Laboratorio de Antibióticos, Bacteriología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
J Infect. 2016 Feb;72(2):152-60. doi: 10.1016/j.jinf.2015.10.008. Epub 2015 Nov 4.
Most available information on carbapenemase-producing Enterobacteriaceae (CPE) is usually associated with specific types of infection or patient or with descriptions of outbreaks. The aim of this study was to comprehensively analyse the clinical epidemiology, clinical features and outcomes of colonisation and infections due to CPE in Spain.
A multicentre prospective cohort study was carried out in 34 Spanish hospitals from February to May 2013. All new patients testing positive for CPE in clinical samples were included. Logistic regression was used to identify predictors of mortality.
Overall, 245 cases were included. The most frequent organism was Klebsiella pneumoniae (74%) and the carbapenemases belonged to the OXA-48 (74%), metallo-β-lactamase (MBL) (24%) and KPC (2%) groups. Acquisition was nosocomial in 145 cases (60%) and healthcare-associated (HCA) in 91 (37%); 42% of the latter were nursing home residents, in whom OXA-48-producing K. pneumoniae ST405 predominated. MBLs and OXA-48 predominated in ICU and medical patients, respectively. Overall, 67% of patients had infections. The most frequent infections identified in this study were urinary tract (43%) and skin structure (21%) infections, and 10% of infections were bacteraemic. Crude mortality was 20%. Inappropriate antibiotic therapy was independently associated with an increased risk of death (OR = 3.30; 95% CI: 1.34-8.11).
We found some differences in the epidemiology of CPE depending on the type of carbapenemase produced. Although a low proportion of CPE infections were bacteraemic, active antibiotic therapy was a protective factor for reducing mortality.
大多数关于产碳青霉烯酶肠杆菌科(CPE)的可用信息通常与特定类型的感染或患者或爆发描述有关。本研究的目的是全面分析西班牙产碳青霉烯酶肠杆菌科在定植和感染方面的临床流行病学、临床特征和结局。
2013 年 2 月至 5 月,在西班牙的 34 家医院进行了一项多中心前瞻性队列研究。所有临床样本中检测到产碳青霉烯酶的新患者均被纳入研究。采用 logistic 回归分析确定死亡率的预测因素。
共纳入 245 例病例。最常见的病原体是肺炎克雷伯菌(74%),产碳青霉烯酶分别属于 OXA-48(74%)、金属β-内酰胺酶(MBL)(24%)和 KPC(2%)组。145 例(60%)为医院获得性感染,91 例(37%)为医疗保健相关感染(HCA);其中 42%为疗养院居民,主要为产 OXA-48 的肺炎克雷伯菌 ST405。MBL 和 OXA-48 分别在 ICU 和内科患者中更为常见。总体而言,67%的患者发生了感染。本研究中最常见的感染分别是尿路感染(43%)和皮肤结构感染(21%),10%的感染为菌血症。粗死亡率为 20%。不适当的抗生素治疗与死亡风险增加独立相关(OR=3.30;95%CI:1.34-8.11)。
我们发现,不同类型的碳青霉烯酶产生的 CPE 流行病学存在一些差异。尽管 CPE 感染的菌血症比例较低,但积极的抗生素治疗是降低死亡率的保护因素。